KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $964.8 million.

  • Alnylam Pharmaceuticals' Receivables - Net rose 17264.73% to $964.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.8 million, marking a year-over-year increase of 17264.73%. This contributed to the annual value of $405.3 million for FY2024, which is 2364.98% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Receivables - Net stood at $964.8 million for Q3 2025, which was up 17264.73% from $567.1 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Receivables - Net's 5-year high stood at $964.8 million during Q3 2025, with a 5-year trough of $110.6 million in Q1 2021.
  • Its 5-year average for Receivables - Net is $302.7 million, with a median of $238.0 million in 2022.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Receivables - Net crashed by 294.43% in 2022 and then soared by 17264.73% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Receivables - Net stood at $198.6 million in 2021, then rose by 19.84% to $238.0 million in 2022, then surged by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024, then surged by 138.03% to $964.8 million in 2025.
  • Its last three reported values are $964.8 million in Q3 2025, $567.1 million for Q2 2025, and $418.0 million during Q1 2025.